Comprehensive Chemical and Pharmacological Analysis of HHCP, HHCPO, THCP, Δ8-THCP, HHCV, and THCV

HHCPO (HHCP-O-acetate), CAS: 2829292-83-1 the acetate ester of HHCP, has the following structural formula. To differentiate it from HHCP, the acetate functional group (-O-COCH3) bonded to the phenolic oxygen is emphasized.

9(R)-Hexahydrocannabiphorol acetate is the chemical name; it is often shortened to HHCPO or HHCP-O. With an acetyl group joined to the molecule's hydroxyl (OH) group, this chemical is basically HHCP.
​

This change is shown by the O-acetate. It is comparable to THC-O-acetate (THC-O), which is THC's acetate ester. In order to create HHCPO, HHCP must first be obtained (by hydrogenating THCP), and the OH group must then be esterified by an acetylation process (often with acetic anhydride).

The end product is a prodrug form, since HHCPO is a lab-derived derivative rather than a naturally occurring cannabinoid.
Weight in formula: 386.58 g/mol
Number of CAS: 2829292-83-1

(for HHCP-O-acetate's particular R,R,R stereochemistry).
Similar/Competitive Products: Like Δ8-THC-O-acetate and Δ9-THC-O-acetate (THC-O), HHCPO is a member of the family of acetate esters of cannabinoids. Since both are acetylated phorols, it is often compared to HHC-O-acetate (the acetate of HHC) and THCP-O-acetate. Other "enhanced" cannabinoids that are marketed as more strong and bioavailable, such as THC-O, PHC (hydroxypropylhexahydrocannabinol),
and even analogs of non-cannabinoids. Similar to THC-O, HHCPO is marketed as a robust, long-lasting cannabinoid that appeals to those looking for hemp products with the highest potency. Health advantages: Although there are no direct studies, it is assumed that HHCPO, a derivative of HHCP, has comparable potential health advantages. Any advantages would follow the body's conversion to HHCP (see Mechanism). In addition to potent THC-like effects, advantages could include pain relief, anti-nausea, muscle relaxation, and stress reduction. If HHCPO is shown to be safe, it may be helpful for long-term symptom management (such as all-night pain or sleeplessness alleviation) due to its claimed very long half-life. However, statements remain anecdotal in the absence of study. Some users claim that HHCPO produces an even "cleaner" or more spiritual high than HHCP, which may indicate a more gradual onset or less anxiety. This might be advantageous for those who find THC or plain HHCP too jittery or abrupt.
It's crucial to stress that any potential health advantages of HHCPO are derived from user reviews and the pharmacology of HHCP, not from research studies.

Possible Effects (Psychotropic and Non-Psychotropic): Because of its pharmacokinetics, HHCPO is said to have even more psychotropic effects per milligram than HHCP. The effects of HHCPO are often described by users as being more strong and persistent once they start, but slower to start. This is comparable to THC-O, a prodrug that produces a strong but delayed high. HHCPO metabolizes into HHCP, which floods the receptors, when it is consumed, particularly orally or by inhalation and subsequent deacetylation in lung tissue. A strong physical high, intense euphoria, and even a more "immersive" or visionary mind experience are all examples of psychotropic effects. Strong sedation and serenity are indicated by what some anecdotal reports refer to as "couch-lock in a concentrate." Similar to HHCP/THC, non-psychotropic physiological effects include analgesia, bloodshot eyes, increased heart rate, and hunger stimulation. Notably, HHCPO is less polar due to the acetate group, which may allow it to effectively pass the blood-brain barrier. As a result, even little dosages may produce a strong high. Many users warn that HHCPO may take 30 to 60 minutes to start working (when vaped), which is longer than HHCP's almost instantaneous impact. After that, it strikes strong and may persist for 6 to 10 hours in total. Some have been taken off guard by this delayed punch, which has caused them to overconsume under the erroneous notion that it was weak. Due to the extended CB1 activation, non-psychotropic consequences throughout the encounter include severe motor impairment and perhaps increased appetite. HHCPO is often utilized for its intoxicating effects rather than its mild ones, and there is no proof of a "clear-headed" dosing range. Product Mechanism (CB1/CB2 Receptor Binding and Metabolic Pathway): Until it is deacetylated to HHCP in the body, HHCPO is an inert prodrug (or at worst a very weak agonist). HHCPO cannot bind to cannabinoid receptors robustly by itself because of the acetate group. But the acetate will be broken down by enzymes (especially esterases) in blood and tissues (including the lungs if vaporized), turning HHCPO into HHCP, which then interacts with CB1 and CB2 receptors as previously mentioned for HHCP. This process is comparable to the brain's conversion of heroin (diacetylmorphine) to morphine: the acetate groups improve transport, which leads to the release of the active ingredient. Acetylation increases the lipophilicity of HHCPO, which may facilitate its entry into the brain prior to activation. Once converted, the resulting 9R-HHCP will bind CB2 to a lesser degree and strongly activate CB1 receptors, producing the psychedelic effects. The metabolic route essentially consists of the following steps: HHCPO (esterase) → HHCP (cytochrome P450) → phase II conjugates and hydroxylated HHCP metabolites (such as 11-OH-HHCP, etc.). According to one research on human hepatocytes, metabolism of acetate analogs like as HHC-O and HHC-P-O always begins with the loss of acetate, producing the parent cannabinoid, which is followed by normal metabolism.

This attests to the first cleavage of the acetate. Crucially, the pharmacodynamics of HHCPO are almost identical to those of HHCP due to its systemic generation of HHCP, although with modified pharmacokinetics (slower release). After conversion, the receptor binding affinity is HHCP (EC₅₀ ~44 nM for CB1 in 9R form). Therefore, HHCPO might be seen as a "trojan horse" that enters the brain and delivers HHCP. Until it is metabolized, HHCPO probably has very little direct receptor binding. Safety: Because of the resultant active molecule, HHCPO has all of the same safety problems as HHCP, plus further worries about the acetate moiety. One significant safety caution is that heating and breathing in HHCPO might result in the inhalation of harmful byproducts. High-temperature vaping of cannabinoid acetates, such as THC-O, may **break down to produce ketene gas, a very harmful lung irritant.
Studies have shown that at around 340°C, aryl acetate cannabinoids, such as THC-O and CBD-O-acetate, produce ketene.

Similar to phosgene gas in toxicity, ketene may cause serious lung damage (think of the 2019 EVALI lung crisis that was connected to vitamin E acetate).

Therefore, vaping HHCPO at high temperatures or on a regular basis may cause significant lung damage.

This serious safety concern is exclusive to acetate formulations. It is highly recommended that users avoid dabbing or high-temp vaping HHCPO, and trustworthy merchants often warn against this. Acute overdose might cause panic attacks, blackouts, or accidents (falls, etc., owing to excessive sedation) in addition to pulmonary issues since HHCPO shares the strong effects of HHCP. The chance of unintentional overconsumption is increased due to its delayed onset; someone may redose believing it isn't working, only to subsequently suffer worsened symptoms. Beyond supportive treatment (such as a benzodiazepine for extreme agitation), there is no recognized counteragent. Although there are no long-term research on HHCPO, there may be undiscovered dangers associated with long-term usage. Since acetate is digested and eliminated, it probably doesn't accumulate, but prolonged inhalation may harm the lungs. Because of its tremendous strength and potential for pulmonary toxicity, HHCPO should be handled with more care than either HHCP or THC-O. In conclusion, HHCPO should only be taken sparingly and ideally orally to prevent the creation of ketene since its safety profile is unclear and possibly dangerous, particularly when inhaled. Side Effects: Although they may last longer, HHCPO side effects are largely the same as those of HHCP. Lethargy, couch-lock, and extreme sedation are typical adverse effects that linger for the majority of the day or night. Common THC-like adverse effects that users often encounter include dry mouth, dry eyes, increased heart rate, anxiety (especially when taking an excessive dosage), and poor coordination. Because of its lengthy persistence, some people may experience "cannabinoid hangover" symptoms, such as tiredness or confused thinking, far into the next day. In essence, a very powerful high may be terrifying for some people, and since HHCPO can strike extremely strongly once digested, there is a risk of higher temporary paranoia or disorientation compared to an equal amount of THC. After utilizing acetate cannabinoids, some users have complained of slight headaches; this might be because to contaminants or the particular metabolism. If too much is taken, it may cause nausea or "green out," which is vomiting from a dosage that is too powerful. Another adverse effect of HHCPO is that it may quickly cause tolerance. Following the first usage, future effects may seem somewhat lessened, which may prompt some people to raise their dosage (which is not advised without care). Some individuals feel that the effects of HHCPO are less likely to create anxiety than those of THC because of the conversion stage, while others may experience the reverse if they overdose. Although this has not yet been shown for HHCPO specifically, prolonged heavy use of HHCPO may cause cannabis hyperemesis syndrome (CHS) in susceptible persons (cyclic vomiting after long-term usage), similar to HHCP. Last but not least, because of its potency, functional impairment is a serious adverse effect; one should avoid doing anything that calls for attention when under its influence. In conclusion, anticipate an extra-strong edible's side effect profile, which may include the possibility of experiencing discomfortably high levels for a long time. Dosing Instructions: HHCPO dosage has to be significantly more cautious than HHCP. For sensitive people, microdoses as little as 1-2 mg (oral) may have discernible effects. Whether in tincture, gummy, or vape form, start new users with little more than 2–5 mg of HHCPO (this may be a single tiny puff or a tiny portion of an edible). Note the delayed onset: HHCPO takes time to convert, so wait at least 30 to 45 minutes after inhalation and at least 1.5 to 2 hours after oral administration to assess the effects. The sweet spot for intermediate users may be between 5 and 10 mg, which may result in a potent high that lasts for the majority of the day. Although advanced users with strong tolerance may consume 10–20 mg, it is typically not recommended to take more than ~20 mg in a single session. Some companies have floated "beginner, intermediate, and advanced" dosing levels (e.g., proposing up to 60 mg for advanced).
​

should be treated with suspicion; most people will discover that such large dosages are quite incapacitating. Dosing may be challenging since HHCPO is sometimes marketed in vape carts; a single 3-second draw might provide many mg. Instead of chain vaping, users should start with a single, tiny puff and wait. To determine the milligrams of edibles or tinctures, utilize measurement devices or items that have undergone laboratory testing. Although the upper barrier is difficult to determine, dosages more than around 30 mg are probably going to have very potent effects with little further benefit. Taking many doses of HHCPO before the first one takes effect is a special danger. Err on the side of too little at all times. Anecdotal data suggests that oral HHCPO has a stronger effect than an equal dosage of HHCP or THC-O. This might be due to the potency and steady production of HHCP, the metabolite. Therefore, think about cutting the amount of THC-O you may consume in half. Additionally, consider the combined potency when combining HHCPO with other cannabinoids (such as in a mixture). In conclusion, to prevent an unpleasant experience with HHCPO, precise, modest dosage and plenty of patience are essential. Contraindications: HHCPO has all of the same contraindications as HHCP (mental illness, cardiac disorders, pregnancy, etc.), but some of them need special attention. Respiratory conditions: HHCPO should not be inhaled by anybody who has lung illness, asthma, or COPD. Vulnerable lungs should not use it because of the possibility of lung irritation or damage (from ketene production and other substances). Repeated vaping of HHCPO is prohibited, even in healthy people; those with pulmonary problems should avoid it altogether or only think about oral methods if absolutely necessary. Children and adolescents: It should go without saying that such a strong drug should never be in close proximity to youngsters; HHCPO may create serious psychological problems in teenagers, and it is only legal for adults. This is particularly crucial during pregnancy and lactation since the baby may be impacted not just by HHCP (from HHCPO) but also by any harmful metabolites of the acetate. Liver impairment: Because HHCPO requires metabolic conversion, a person with liver impairment may process it in an unpredictable way, which might result in greater amounts for longer periods of time (or, on the other hand, ineffective conversion). Patients with liver illness should use caution and refrain from utilizing drugs that are not authorized, such as this one. Use with pharmaceuticals: Due to the prodrug nature, there is a potential risk that certain medications, especially those that impact esterases, such as cholinesterase inhibitors, may interfere with the breakdown of HHCPO. Although it is uncommon, if taking many drugs, one should exercise caution and preferably seek advice from a qualified doctor. Elderly people: Seniors should normally stay away from HHCPO since they are more likely to have negative cardiac effects and falls due to drowsiness and low blood pressure. In conclusion, whenever HHCP is present, HHCPO is contraindicated due to extra lung health and metabolic problems. Legality: Although HHCPO has an even lesser profile, its legal standing closely resembles that of HHCP.
HHCPO is not specifically scheduled by the federal government of the United States. Although it was not included in the 2018 Farm Bill as an isomer or derivative of HHCP, manufacturers contend that it is lawful as long as it is made from hemp. HHCPO is often marketed as "hemp-derived" as it is usually manufactured from hemp-extracted CBD → Δ8-THC → HHCP → HHCPO. For HHCPO specifically, there is currently no DEA judgment. The DEA could, however, classify it as an analog of a Schedule I narcotic (THC) since it is an acetate of a THC analog. It now operates in a gray market and is not nationally controlled nor scheduled.
United States (State): Anywhere that HHCP or THC-O is prohibited, so is HHCPO. By extension, HHCPO would be illegal in those places that prohibited THC-O acetate and related substances. In Iowa, Nebraska, Louisiana, Washington, Utah, and other states, for instance, "tetrahydrocannabinol acetate esters" or all synthetic analogs are prohibited by wide wording.

As of late 2024, HHCPO was either expressly or implicitly prohibited in around a dozen states, including Alaska, Arizona, Arkansas, Colorado, Delaware, Hawaii, Idaho, and Montana. However, it was still permitted in Alabama, Florida, Illinois, Wisconsin, and many more states, according to industry sources.

(This list is comparable to those that prohibit delta-8 THC.) Since HHCPO is a more recent regulation, several states do not specifically identify it, but they would include it in statutes that prohibit "any hemp-derived substance with similar effects to delta-9 THC." Notably, jurisdictions that regulate cannabis for adult use, like as Oregon, often prohibit unregulated analogs. For example, Oregon has prohibited the sale of synthetic cannabinoids outside of licensed establishments, rendering HHCPO unlawful in general retail. As of 2025, California has not officially outlawed HHCPO and presently allows sales of hemp derivatives, however this might change with future legislation. In conclusion, HHCPO's state legality map is roughly the same as that of HHCP or THC-O: it is lawful in certain states under hemp legislation but banned in others that adopted a more stringent position. Interested parties should check the current hemp cannabis legislation in their state.
Internationally, HHCPO would almost always be regarded as a prohibited substance. Any nation that outlaws HHCP will also outlaw its acetate. For example, in 2023, Japan specifically outlawed HHCP-O-acetate in addition to HHCP.

HHCPO is probably considered a designer drug by the EU, and it would be confiscated if discovered. Reports of vape items containing HHCPO being confiscated in Europe have surfaced (for example, an EU Early Warning System notice of HHCPO in joint materials in 2023).

HHCPO would be considered a forbidden THC analog in countries with analog legislation (such as Australia, New Zealand, and many Asian countries), suggesting that authorities see it as a regulated new drug. This chemical has no valid exemptions for industrial or medicinal usage. As a result, HHCPO is essentially banned everywhere except in the few US states where it is accepted.
In conclusion, HHCPO has very limited legality. It is marketed online in the US on a grey market, but it is unlawful in other countries and might be banned by any state at any time. Regulators may take action against acetate cannabinoids sooner rather than later because of the increased health hazards.
Hot Search Terms: HHCP-O acetate, hexahydrocannabiphorol acetate, HHCPO, effects, safety, legal status, dosage, vape ketene HHCPO, HHCPO vs. THC-O 


THCP (Δ9-Tetrahydrocannabiphorol)


Tetrahydrocannabiphorol, or Δ9-THCP, CAS: 54763-99-4  structural formula. It has the same structure as traditional THC, but instead of pentyl, it contains a heptyl side chain (7 carbons). Its greater efficacy is mostly due to its longer side chain (right side in the picture).

Δ9-Tetrahydrocannabiphorol (abbreviated THCP in science) is the chemical name. The notation Δ9-THC-C7 or Δ9-THC-heptyl is sometimes used.
demonstrating that it is a seven-carbon side-chain homolog of Δ9-THC. 3-Heptyl-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-6H-benzo[c]chromen-1-ol is the long IUPAC name.


Italian researchers discovered THCP as a naturally occurring component of a cannabis plant (strain FM2) in late 2019.
This finding showed that cannabis generates small amounts of longer-chain cannabinoids like THCP and its matching CBDP in addition to the well-known pentyl side-chain cannabinoids (such THC, CBD). Commercial THCP is made semi-synthetically, generally by chemically altering CBD or Δ9-THC derived from hemp (e.g., olivetol coupling with a C7 alkyl side chain intermediate), since THCP is found in nature only in tiny levels (micrograms per gram of plant, typically).

Weight in formula: 342.51 g/mol
Number of CAS: 54763-99-4

Similar/Competitive Products: THCP is often contrasted with its shorter pentyl analog, Delta-9 THC, and its isomer, Delta-8 THC. Since it is regarded as one of the strongest naturally occurring cannabinoids, its rivals are mostly synthetic, like the aforementioned HHCP or HU-210, a lab-made counterpart that is significantly more powerful than THC. High-THC cannabis extracts and other new cannabinoids, such as THCjd (the alleged 8-carbon side chain) and THCB (the butyl side chain), are competitors of THCP products in the consumer market. The delta-8 double bond isomer of THCP, Δ8-THCP (discussed next), is another comparable molecule. Health Benefits: Since THCP is so new, confirmed health benefits are theoretical. Essentially, THCP has become a standard for "ultra-potent" cannabinoids, often promoted alongside analogs like THC-O, HHC-P, and Delta-11 THC. It may, however, provide stronger THC medicinal benefits since it binds to cannabinoid receptors more strongly than THC. Analgesia (pain reduction) is one potential advantage; THCP may be more effective than THC in reducing pain at lower dosages.

Through CB2 activation, it may potentially have anti-inflammatory properties, which suggests use in diseases like arthritis. Similar to THC but maybe more effective when THC isn't (because to tolerance), some studies have noted that its affinity might be used for anti-nausea treatment or hunger stimulation in chemotherapy patients. THCP may also have longer-lasting effects on sleeplessness, intraocular pressure (glaucoma), and muscular spasticity, all of which are known to be improved by cannabinoids. One unusual approach is that since THCP was discovered in an Italian medicinal cannabis strain, people are curious to know whether its presence improved patient outcomes, such pain management. Notably, a 2021 research on mice discovered that THCP had pharmacological effects similar to those of THC (hypothermia, analgesia, and locomotor inhibition) at dosages around 1/3 of THC's dose, indicating its potential as a more effective treatment.

Health claims are still speculative until official research is completed, but given its potent and long-lasting effects, THCP may play a part in future cannabis-based medications provided its safety is controlled. Possible Psychotropic and Non-Psychotropic Effects: THCP is a potent psychotropic substance. Actually, according to laboratory experiments, its affinity for CB1 receptors is around 33 times more than that of Δ9-THC.

It corresponds to an even more intense high. Users of THCP (either alone or in boosted products) say that although its euphoric effects are comparable to those of THC, they are noticeably stronger and often last longer. Strong euphoria, a changed sense of time, an enhanced enjoyment of music and color, and a profound relaxation of the body may all result from even tiny doses of THCP (e.g., a few milligrams). Depending on the dosage and method, the high may last anywhere from 4 to 8+ hours. It usually peaks later and lasts longer than a similar THC dose. Near-maximal CB1 activation may result in a kind of "ceiling" of CNS depression, which is probably why some people experience the mental impact as being stronger and more sedative than ordinary THC. Although this is anecdotal, some users have reported increased mental clarity at relatively low dosages of THCP, which may be due to its greater action on CB2 or partial agonization of CB1 without complete activation. Classic physical relaxation, analgesia, and increased appetite are examples of non-psychotropic effects (THCP, like THC, may induce hunger). One distinction is that THCP may cause more severe impairment of motor coordination; it slows you down in a manner akin to that of a drug. Additionally, since THCP has a greater receptor activity, tachycardia (rapid pulse) and a reduction in blood pressure may be more noticeable. It's interesting to note that since THCP binds CB1 so firmly, it may promote increased receptor internalization or downregulation with repeated usage, which might accelerate the fading of its effects over time (i.e., tolerance may develop rapidly). The overall impact profile of THCP is basically "like THC but turned up to eleven": very psychoactive, causing immense pleasure for some users and potential pain for others who take excessive amounts. THCP functions as a complete or strong partial agonist at CB1 receptors, according to the product mechanism (CB1/CB2 Receptor Binding Affinity and Action). K_i values of around 1.2 nM at CB1 and 6.2 nM at CB2 have been reported in binding experiments.


Comparing these results to the K_i ~40 nM of Δ9-THC at CB1, they show an exceptionally strong affinity. Practically speaking, relatively low amounts of THCP may activate CB1 receptors. It probably functions as a high-efficacy agonist, maybe even more so than THC, a partial agonist. In a mouse model, the Italian discovery study discovered that THCP had more cannabimimetic effects than THC at the same dosage.

indicating a high level of intrinsic activity in addition to affinity. Additionally noteworthy is THCP's affinity (6.2 nM) for CB2 receptors, which is about an order of magnitude greater than THC's. This suggests that THCP may have potent peripheral cannabinoid receptor engagement (immune cells, etc.), resulting in peripheral analgesic and anti-inflammatory effects. By accessing more hydrophobic areas in the CB receptor binding pocket, the extended alkyl side chain (C7) is known to improve receptor-ligand interactions.

In essence, THCP has a larger impact than THC because it "fits" into the CB1 receptor more securely. The same downstream pathways—adenylate cyclase inhibition, ion channel modulation, and neurotransmitter release inhibition (GABA, glutamate, etc.)—are triggered once THCP binds to CB1, resulting in psychoactive effects. Similar to THC, THCP is metabolized by liver enzymes to produce 11-hydroxy-THCP and THCP-COOH (carboxy metabolite), albeit not much research has been done on these metabolites. These metabolites could have even longer half-lives because of the longer chain. In addition, THCP probably has a little longer half-life in the body than THC, which prolongs its effects. In conclusion, THCP works by binding to the same receptors as "supercharged THC," but with far higher affinity and potential effectiveness, which increases the signaling of cannabinoid receptors. Crucially, THCP is effective at very low dosages; studies revealed that it produced cannabimimetic effects in rats at 5 mg/kg, whereas THC required 10 mg/kg to produce comparable effects.


This supports the receptor binding data, showing that THCP is around 2-3 times more effective than THC in vivo (although the 33x affinity is partially translated since it is a partial agonist). Additionally, its CB1 affinity was almost 13 times greater than that of the shorter counterpart THCB.

Both its tremendous high and its potential for therapeutic use are supported by THCP's profound CB1 and CB2 activation. Safety: With the exception of the fact that THCP is more powerful than THC, the safety profile of THCP is essentially extrapolated from THC. Acute toxicity: As cannabinoids generally have a strong safety margin (no fatal overdose instances by receptor activation alone), THCP has not shown any symptoms of organ toxicity or deadly consequences in the limited animal tests. However, there are more behavioral hazards (such as panic attacks and accidents) because of the extreme psychoactivity. Because a little goes a long way, users may unintentionally take too much and suffer from acute anxiety, hallucinations, or vomiting, which is a serious safety problem. For some people, experiencing an intensely powerful high may be traumatizing. A person with poor cardiovascular health may have significant tachycardia and hypotension due to THCP's high CB1 activation, which might be harmful (risk of fainting or arrhythmia). There is no proof that THCP is particularly harmful to organs; it probably isn't because of its structural similarity to THC, which is generally safe for organs. However, unanticipated consequences cannot be ruled out due to a lack of study. Given that even ordinary high-THC cannabis may sometimes cause psychotic episodes, one concern is whether THCP might more easily cause psychosis in susceptible people than conventional THC. Severe receptor activation may make that danger higher. Dependency and tolerance: Regular THCP usage may accelerate the downregulation of CB1 receptors, which would accelerate the development of tolerance. Regularly switching from THC to THCP may help someone become substantially less sensitive to ordinary cannabis. Similar to THC, persistent users may have withdrawal symptoms (dysphoria, sleeplessness, anger, etc.); these symptoms may be a little more severe if their brain has adapted to the higher agonist. Long-term safety: THCP's safety is completely unknown. At equal molar intakes, THCP may share or even intensify the cannabis hyperemesis syndrome, cognitive abnormalities, and putative subtle memory effects linked to chronic high-dose THC. Another problem is that purity is a concern since THCP is often synthesized. Black-market THCP may include impurities (such as leftover reagents or unexpected isomers) that might be harmful to one's health. Since there is no safety supervision, goods differ from a regulatory standpoint. In conclusion, users should exercise considerable caution, even if THCP's acute safety seems to be comparable to that of highly strong cannabis. Until more information is obtained, it should be regarded as a very potent drug with all of THC's hazards exacerbated. Side Effects: THCP is likely to have side effects similar to those of THC, however perhaps more severe. Anxiety and paranoia are frequent adverse effects; particularly in novice users, high dosages may cause panic attacks or paranoid ideas. Cognitive impairment: Similar to THC, but maybe more severe, THCP will result in short-term memory problems, trouble focusing, and confusion. Sensory changes: at high dosages, there may be visual or auditory distortions (light trails, sound amplification), which may even resemble mild hallucinations. blood pressure swings and an elevated heart rate (feeling dizzy). As with any potent CB1 agonist, dry mouth, red eyes, and increased hunger are all but certain. Motor impairment: When under the influence of THCP, driving is very risky since it may drastically delay response times and impair coordination. Another negative effect to be aware of is extended sedation. Because of how long the peak high may last, users often experience extreme fatigue or sluggishness as it wears off. This may cause grogginess the next day. After extensive THCP usage, some users have suffered headaches; it's unclear whether this is because to contaminants, dehydration, or the chemical itself. As a result of transitory hypotension following CB1 activation, dizziness is also often experienced, particularly if one gets up fast. Side effects range from enjoyable (such as laughter and relaxation) to unpleasant (such as nausea and anxiety) as dose rises. As with particularly potent cannabis edibles, nausea and vomiting may occur as a side effect if a person "greens out" on too much THCP. THCP probably follows the same pattern as THC, which is anti-emetic at normal dosages but may flip and induce vomiting at high concentrations. Rarely, those who are susceptible or who use drugs at excessively high dosages may have transient psychosis (delusions, disorientation); these adverse effects go away as the medication wears off. It's also important to note that time distortion is a side effect; if someone is uncomfortable, minutes may seem like hours, making the encounter seem endless. Physical side effects might include shaking or tremors (some high-THC users develop muscular tremors). Every adverse effect is dose-dependent; at extremely low dosages, THCP may only provide mild mood enhancement and dry mouth. However, be prepared for the whole range of cannabis adverse effects, which are often exacerbated, while using recreational dosages. Dosing Guidelines: In order to prevent THCP's negative effects, it is essential to take it as prescribed. For many individuals, THCP is 5–10 times more powerful by weight than Δ9-THC, hence moderate dosages are advised. A starting dosage of 1-2 mg of THCP is often recommended for novices.

To enable low dosage, a lot of THCP products, such tinctures or gummies, are made with microgram accuracy (e.g., 1 mg per drop or per gummy). One or two inhales (a few milligrams at most) is more than enough to begin smoking or vaping a product that contains THCP. For intermediate users, 3–5 mg of THCP may provide a strong but controllable high.

High-tolerance advanced users sometimes take 5–10 mg at a time.

However, even for them, taking more over 10 mg might result in significant side effects and declining results. For everyone but the most THC-tolerant people, single dosages should be limited to around 5 mg. Keep in mind that these milligram amounts represent active compounds rather than plant material; for example, 5 mg of THCP may have an impact that is comparable to more than 50 mg of normal THC, which is a high dosage. Since THCP may behave as a moderate stimulant or have little effects at very low dosages, microdosing (sub-milligram doses) is not often recorded. For daytime focus without drunkenness, some people may try ~0.5 mg; nevertheless, the outcomes vary. Time to onset: Inhalation may cause effects to begin within 5 to 15 minutes, peak between 30 and 60 minutes later, and linger for hours. If taken orally (for example, in oil form), the duration may be as long as 8+ hours, with an onset of 1-2 hours. As a result, wait at least two to three hours to get the full effects of edibles and tinctures before re-dosing. Dosing might be challenging since THCP is often coupled with other cannabinoids in goods (to modify its effects); as an example, a blend may include CBD, which can lessen the high. Tolerance: Regular use of THCP will rapidly increase tolerance; after a week or two of regular usage, one may need somewhat greater dosages. In order to maintain its efficacy and prevent excessive tolerance, which causes conventional THC products to feel weak, it is advisable to take THCP rarely. In conclusion, start very low (1-2 mg) and only gradually raise on different occasions. Although users who have used potent edibles (50+ mg THC) before may be able to manage a little more, they should nonetheless respect the intensity of THCP. To ensure accuracy, always measure dosages carefully. If you're using a concentrate, it can be worthwhile to dilute it or use volumetric dosing, which involves dissolving a specific quantity in a carrier oil. Contraindications: Because of the potency of THCP, there are a number of contraindications that are similar to those for high-THC cannabis but more stricter:
Breastfeeding with pregnancy: Completely contraindicated. Given its strength, THCP may be much more disruptive than THC, which has shown possible developmental problems. Pregnant women are highly recommended to stay away from any exposure.
Cardiovascular Problems: THCP should not be used by anybody who has a history of heart attacks, angina, arrhythmias, or uncontrolled hypertension. Strong CB1 activation may stress a weak heart by causing tachycardia and blood pressure fluctuations.

Very high potency cannabis usage has been linked to myocardial infarction cases in young males; THCP may raise this risk because of increased heart stress from anxiety or vasodilation.
Mental Health Conditions: People should stay away from THCP if they have a personal or family history of schizophrenia or psychosis. It is well recognized that high-potency cannabis may cause psychotic episodes in vulnerable people. Similarly, the strong psychological effects of THCP may exacerbate severe anxiety condition.
Adolescents: Since brain growth continues until the mid-20s, introducing a very powerful cannabinoid might disrupt motivation, memory, and neurological development (as high-THC usage has been linked to). Therefore, under no circumstances should children consume THCP (for similar reasons, the age is 21 in locations where cannabis is allowed).
Low Tolerance/First-Time Users: Although it may seem strange, THCP is not recommended for first-time cannabis users. First, some acquaintance with weaker cannabis is advised. It might be stressful and even painful to dive right into THCP if you have no idea what a cannabis high feels like.
Use in Combination: It might be dangerous to use THCP in conjunction with other drugs. For instance, combining with dissociatives or psychedelics may result in erratic mental states. The danger of blacking out and impairment might be significantly increased even by drinking with THCP. Therefore, using THCP in combination with other intoxicants is not advised.
Certain Medical Conditions: Although THCP is not especially hepatotoxic, those with severe liver or renal illness may also wish to avoid it since any problems with metabolism may extend its effects or lead to buildup. Additionally, metabolite excretion may be slower in those with renal problems. People with epilepsy should exercise caution; although CBD is generally anti-epileptic, some people may have seizures while taking large quantities of THC. It is unknown how THCP affects seizure threshold, but if seizures are a problem, one should exercise caution or stay away from it.
Generally speaking, anybody who is not well or who is unfamiliar with cannabis should stay away from THCP. This substance should only be used by adults under strict supervision. It is advisable to avoid using it altogether or to use far less powerful substitutes if there are any contraindications.
Legality: THCP's legal situation is unclear and changing.
United States (Federal): The Controlled Substances Act does not specifically mention THCP. However, one may argue that it is a similar substance to Δ9-THC (Schedule I). The 2018 Farm Bill adds complexity: some claim that THCP generated from hemp is legally allowed if its Δ9-THC level is less than 0.3%. In fact, the DEA has not yet released any particular guidelines on the authorized online sale of THCP generated from hemp in the United States. However, since THCP is "substantially similar" to THC in both structure and impact, legal experts often warn that the Federal Analogue Act may apply. Until enforcement or clarity occurs, THCP remains in a federal gray area: it is not specifically scheduled, but it may be lawful if it is derived from hemp. Since THCP has not received FDA approval for any purpose, it is only sold as a "research chemical" or as a supplement.
United States (State): There are significant differences in state legislation. Although most states have not officially listed THCP in their laws as of 2024, many have prohibited all THC isomers and analogs, particularly those that have outlawed Delta-8. In at least a dozen states, including Alaska, Arizona, Arkansas, Colorado, Delaware, Idaho, Iowa, Mississippi, Montana, Rhode Island, Utah, and Vermont, THCP is either banned or probably unlawful, according to industry surveys.


These states' wide wording prohibits any synthetic cannabis analogs, including "tetrahydrocannabinols other than delta-9." Since New York has outlawed the production of any cannabis product outside of its authorized program, THCP sales in conventional retail establishments are essentially prohibited. However, THCP is now lawful in areas like Florida, Texas, Illinois, and others where hemp-derived cannabinoids are still permitted. For example, Texas has not enacted a statewide prohibition on Delta-8 or THCP, and Florida has not amended its laws to do so, therefore they are marketed freely. Although California passed a legislation mandating testing and age restrictions on such products, the state still permits hemp cannabinoids, including THCP. If THCP is found in licensed marijuana extracts, it counts toward the overall THC potency in jurisdictions where cannabis is legal (some states define THC to include all analogs in their regulated products). However, the majority of dispensaries don't test or label THCP content precisely. THCP is primarily promoted by the hemp industry. It's important to verify state laws. For instance, Indiana permits hemp derivatives and has not outlawed THCP, but Kentucky outlawed all intoxicating hemp products in 2023 via legislation that indirectly addresses THCP. Although the patchwork is intricate, as a general rule, THCP will be prohibited in a state if Delta-8 THC is. On the other hand, THCP probably passes as well (for the time being, at least) if Delta-8 is permitted.
International: Since THCP is a derivative of THC, it is prohibited in the majority of nations. According to the United Nations drug treaties, "cannabis and cannabis resin, and extracts and tinctures of cannabis" are prohibited; THCP would be considered a cannabis extract if it were obtained from the plant. Even in nations that have legalized or tolerated cannabis, such as Canada and Europe, cannabinoids are still only available via controlled channels. Any isolated THCP would be seen as being comparable to THC in Canada; it would only be permitted if it was sold by a licensed manufacturer in a cannabis product that was legal, which it isn't at the moment; no goods are purposefully made with THCP. Similar to THC, THCP is not well-known in EU regulatory documents; nonetheless, it is probably classified as a Schedule I banned drug or covered by generic regulations (some nations have a general definition of cannabinoids under control). For example, after seeing their development, Switzerland outlawed THCP and related cannabinoids in October 2023.

It was probably added to the list of prohibited drugs in Italy, where it was found (THCP would not be exempt, although THC in hemp is limited by the Italian Ministry of Health). Asia/Pacific: THC analogs are strongly prohibited in Japan and many other Asian nations. THC and its analogs are classified as Schedule 9 drugs in Australia and New Zealand. UK: As a cannabis derivative, THCP would be classified as a Class B prohibited substance. The UK does not distinguish between these analogs legally, and the Psychoactive Substances Act would likewise prohibit its usage outside of medical settings. One noteworthy detail is that, since THCP is a naturally occurring compound in cannabis, a person utilizing full-spectrum cannabis extract may unintentionally contain THCP. However, this is irrelevant from a legal standpoint because the extract is still classified as cannabis. Basically, don't try to purchase or send THCP outside of the United States. In the majority of jurisdictions, it is fair to presume that it is prohibited. Only in some nations with weak innovative drug enforcement would it be considered quasi-legal, but that is dangerous. The legality of THCP per country is as follows: it is prohibited in the great majority of countries (treated like THC), with the exception of the United States (and maybe a few other hemp-friendly nations) where there is a gray area that permits it to pass through a loophole. As regulations catch up, that loophole can shut due to increased scrutiny.
Tetrahydrocannabiphorol, THCP cannabinoid, THCP potency 33x, THCP vs. THC, THCP effects, THCP legality, THCP negative effects, THCP dose, and THCP binding affinity are some of the most popular search terms.